Sopfarma AD was given license for 54 types of medicine in 2006, the company’s registration papers on the BSE-Sofia state.

During the past year the company has started a project for a new logistics and new tablet plant.

The market share of the company on the Bulgarian pharmaceutical market for 2006 was 9 %.
Sopfarma is the leading Bulgarian pharmaceutical company on the Russian market. The company is responsible for 1% of the import of medical products on the Ukrainian market and holds 1% of the Ukrainian pharmaceutical market.

In 2006 Sopfarma acquired 70 % of the capital of Mineralcommers Ltd Stara Zagora which is Bulgaria’s only manufacturer of amorphous silica – a component used in the cosmetic and chemical industry.

Sopfarma AD acquired 51.34% of Biopfarma Engineering AD Sliven, a manufacturer of medical products and veterinary patent medicines, as well as 68.73% of the capital of the distributor Sopfarma Trading AD.

Towards 31st December 2006 the company’s participation in Sopfarma Trading was 99.62%.

Also in Decmber 2006 the Executive Director Ognyan Donev founded representations of the company in Beograde, The Republic of Serbia and Montenegro.

Sopfarma AD finished last year with a net profit of BGN 22.034 mln against BGN 30.429 mln for the previous year. The company’s net sales revenues amounted to BGN 151.973 mln in comparison to BGN 142.459 mln.

Sofia AD and Telso AD own respectively 25.58% and 23.84 % of the company’s capital and Telekomplect AD and Gramercy Emerging Matkets Fund own 21.49 % and 17.13%

During today’s trading session a total of 2081 shares of the company were sold at levels of BGN 7.14 to BGN 7.65 each.